Author

D. Bottomly

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

S. McWeeney· 2 shared A. Beall· 1 shared B. Druker· 1 shared B. J. Druker· 1 shared B. M. Smith· 1 shared C. E. Tognon· 1 shared D. J. Coleman· 1 shared E. Demir· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

S. McWeeney

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

W. M. Yashar, B. M. Smith, D. J. Coleman, J. VanCampen, G. Kong, J. Macaraeg, J. Estabrook, E. Demir, N. Long, D. Bottomly, S. K. McWeeney, J. W. Tyner, B. J. Druker, J. E. Maxson, T. P. Braun

This study shows that combining FLT3 and LSD1 inhibitors synergistically kills FLT3-mutant AML cells by disrupting the MYC super-enhancer complex.

bioRxiv · Jan 17, 2022 · PreprintCancer Biology

A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance

S. K. Joshi, S. Sharzehi, J. Pittsenbarger, D. Bottomly, C. E. Tognon, S. McWeeney, B. Druker, E. Traer

This study identifies a novel FLT3 mutation, N701K, that confers resistance to gilteritinib by blocking its binding, and suggests switching to type 2 FLT3 inhibitors may be effective.

bioRxiv · Jan 27, 2021Cancer Biology

Mucin 4 Protects Female Mice from Coronavirus Pathogenesis

J. A. Plante, K. Plante, L. Gralinski, A. Beall, M. T. Ferris, D. Bottomly, R. R. Green, S. McWeeney, M. T. Heise, R. S. Baric, V. D. Menachery

This study identifies Muc4 as a protective factor in female mice against SARS-CoV pathogenesis, showing sex-specific effects without altering viral titers.

bioRxiv · Feb 19, 2020 · PreprintMicrobiology